ORIGINAL CLINICAL SCIENCEAn aging population of patients with cystic fibrosis undergoes lung transplantation: An analysis of the ISHLT Thoracic Transplant Registry
Section snippets
Study design
Using data provided via a data sharing agreement by the ISHLT Thoracic Transplant Registry (www.ishlt.org/registries), a multinational database of thoracic organ transplants, we conducted a retrospective cohort study of reported deceased-donor primary lung-alone transplants in patients with CF reported to the Registry from January 1, 2005 through December 31, 2014. The study follow-up termination date of December 31, 2015 allowed for a potential minimum of 12 months post-transplant follow-up.
Study cohort and age sub-groups
A total of 5,613 lung transplant recipients had the primary diagnostic indication of CF-associated lung disease, including 610 (10.9%) pediatric recipients and 5,003 (89.1%) adult recipients. Of the adults, 73.3% were aged 18 to 39 years and 15.9% were aged ≥40 years.
Number transplanted and age of recipients during the 2 study eras
The number of recipients with CF increased significantly from 2,508 in Era I to 3,105 in Era II (p < 0.001), mainly because of an increase in the number of adult transplants (Figure 1). Thus, the proportion of pediatric recipients
Discussion
This study demonstrates that the number of transplants reported for a primary diagnostic indication of CF-associated lung disease has increased during the past decade. During this time, the proportion of transplants for CF in adults has increased, whereas the proportion in children has not. Adult patients from 2 age groups undergoing transplantation for CF-associated lung disease experienced a better survival than pediatric transplant recipients, and adult recipients of at least 40 years of age
Disclosure statement
The authors have no conflicts of interest to disclose.
The authors acknowledge Leah B. Edwards’ tremendous expert input and statistical support with the data analysis and Roger D. Yusen's great assistance with the manuscript revision.
This work was partially presented at the 36th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation in Washington D.C., USA.
References (37)
- et al.
The Registry of the International Society for Heart and Lung Transplantation: Thirty-third adult lung and heart-lung transplant Report-2016; focus theme: Primary diagnostic indications for transplant
J Heart Lung Transplant
(2016) - et al.
The Registry of the International Society for Heart and Lung Transplantation: Seventeenth official pediatric lung and heart-lung transplantation report – 2014; Focus theme: Retransplantation
J Heart Lung Transplant
(2014) - et al.
The Registry of the International Society for Heart and Lung Transplantation: Eighteenth official pediatric lung and heart-lung transplantation report – 2015; Focus theme: Early graft failure
J Heart Lung Transplant
(2015) - et al.
The Registry of the International Society for Heart and Lung Transplantation: Nineteenth pediatric lung and heart-lung transplant Report - 2016; focus theme: Primary diagnostic indications for transplant
J Heart Lung Transplant
(2016) - et al.
True survival benefit of lung transplantation for cystic fibrosis patients: The Zurich experience
J Heart Lung Transplant
(2009) - et al.
Changing demographics and outcomes of lung transplantation recipients with cystic fibrosis
J Heart Lung Transplant
(2016) - et al.
Growing old with cystic fibrosis—The characteristics of long-term survivors of cystic fibrosis
Respir Med
(2009) - et al.
The registry of the international society for heart and lung transplantation: Thirty-fourth adult lung and heart–lung transplantation report—2017; focus theme: Allograft ischemic time
J Heart Lung Transplant
(2017) - et al.
Registry of the International Society for Heart and Lung Transplantation: Twentieth pediatric lung and heart-lung transplantation Report—2017; focus theme: Allograft ischemic time
J Heart Lung Transplant
(2017) - et al.
A consensus document for the selection of lung transplant candidates: 2014—An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
(2015)
Age-related survival disparity associated with lung transplantation in cystic fibrosis: An analysis of the registry of the International Society for Heart and Lung Transplantation
J Heart Lung Transplant
Outcomes of adolescent recipients after lung transplantation: An analysis of the International Society for Heart and Lung Transplantation Registry
J Heart Lung Transplant
Survival in pediatric lung transplantation: The effect of center volume and expertise
J Heart Lung Transplant
Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: A pooled analysis
Lancet Respir Med
Increased prevalence of colonic adenomas in patients with cystic fibrosis
J Cyst Fibros
Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosis
J Cyst Fibros
Body mass index and its effect on outcome in children after lung transplantation
J Heart Lung Transplant
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Twenty-first pediatric lung and heart-lung transplantation report - 2018; focus theme: Multiorgan transplantation
J Heart Lung Transplant
Cited by (21)
How Would We Treat Our Own Cystic Fibrosis With Lung Transplantation?
2024, Journal of Cardiothoracic and Vascular AnesthesiaPathological remodeling of distal lung matrix in end-stage cystic fibrosis patients
2022, Journal of Cystic FibrosisCitation Excerpt :Cystic fibrosis (CF) is characterized by a pathologic cascade of impaired ion transfer, dysregulation of airway surface liquid and mucus, inability to clear infection, chronic inflammation, and ultimately end-stage lung disease necessitating transplantation [1,2].
Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease?
2022, ChestCitation Excerpt :Furthermore, no data on long-term follow-up are currently available and it remains unknown whether elexacaftor-tezacaftor-ivacaftor treatment would provide survival benefits, over lung transplantation, in patients with end-stage lung disease. Data on lung transplantation have a well-demonstrated survival benefit for adult patients with cystic fibrosis.24-26 In pediatric patients, reports demonstrate lower survival when compared with adults,24,25,27,28 with a median survival of about 3.5 years for pediatric patients.25,29
The evolution of the ISHLT transplant registry. Preparing for the future
2021, Journal of Heart and Lung TransplantationAutomated antimicrobial susceptibility testing of slow-growing Pseudomonas aeruginosa strains in the presence of tetrazolium salt WST-1
2021, Journal of Microbiological MethodsCitation Excerpt :Lung transplantation (LTx) remains as a last resort for patients with advanced lung infections due to the limited efficacy of conventional antibiotic therapies. The total number of adult CF patients undergoing LTx has increased by 23.8% within a time-span of 5 years (Benden et al., 2019). These care measures contribute to a significant increase in the costs of CF-related hospitalization (Van Gool et al., 2013; Perkins et al., 2021).